For instance, histone deacetylase inhibitors (HDACIs), such as MS275, suberoylanilide hydroxamic acid and valproic acid, sensitize GBM cells to TRAIL-induced apoptosis in vitro and in vivo through c-myc-downregulated c-FLIP [129], suggesting the use of HDACIs in order to prime GBM for TRAIL-induced apoptosis by targeting c-FLIP. The gene discussed is CFLAR; the disease is glioblastoma.